Sanofi fi­nal­ly man­ages to close on a buy­out – but it’s not a game chang­er

Sanofi $SNY has fi­nal­ly man­aged to com­plete a buy­out — though it’s a far cry from the kind of trans­for­ma­tion­al block­buster deal it’s been on the hunt for.

Af­ter miss­ing out on auc­tions for Medi­va­tion and Acte­lion, the French phar­ma gi­ant has snagged Pro­tein Sci­ences and its quadri­va­lent flu vac­cine Flublock, ap­proved last fall. Sanofi is pay­ing $650 mil­lion in cash and of­fer­ing up $100 mil­lion more in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.